S. B. Erofeeva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
S. B. Erofeeva has a total of 135 co-authors. Here are the top co-authors by number of shared publications:
- R. F. Khamitov
Kazan State Medical University
3 shared publications - A. A. Kaznina
Privolzhsky Research Medical University
2 shared publications - A. Kh. Safina
LLC "Dr. Fomin’s clinic
2 shared publications - A. V. Skibitskiy
Kuban State Medical University
2 shared publications - A. Yu. Vaskin
Association "Eurasian Association of Therapists
2 shared publications - Albert S. Galyavich
Kazan State Medical University
2 shared publications
Latest Publications
- Open Access
- 4 June 2026
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 31 (4) , 6424
Incidence of chronic obstructive pulmonary disease in the newly diagnosed microalbuminuria population: retrospective analysis of the AURA registry database
Aim. To analyze the phenotypes of patients at highest risk for albuminuria (AU) in a population of patients without diabetes and to estimate its prevalence in the identified phenotypes. Material and methods. A total of 4580 patients over 40 years of age without type 1 or 2 diabetes, who had not previously been diagnosed with chronic kidney disease, were included in a real-world practice registry of AU detection in patients with previously undiagnosed CKD — AURA. The registry design did not include patient follow-up. AU was determined using sensitive micral-test strips, with an AU cutoff of 20 mg/L. Results. AU ≥20 mg/L was present in 64,9% of cases. According to univariate analysis, patients with AU compared with those without it were more likely to have the following risk factors: hypertension (79% vs 71,5%), male sex (44,2% vs 38,6%), smoking (31% vs 25,2%), metabolic syndrome (32% vs 23,4%), as well as diseases such as coronary artery disease (35,5% vs 29,7%), heart failure (41,5% vs 35%), atrial fibrillation (17,3% vs 12,5%), prediabetes (14,7% vs 8,9%), chronic obstructive pulmonary disease (COPD) (7,67% vs 3,76%), chronic cystitis (5,35% vs 3,49%). A multivariate model revealed that age (with each 1-year increase in age, the risk of AU increased by 2%, p-value Conclusion. A multivariate analysis of AURA registry data confirmed that AU is independently associated with conditions such as post-infarction cardiosclerosis, atrial fibrillation, prediabetes, metabolic syndrome, chronic cystitis, and COPD. Of particular interest is the study and follow-up of patients with COPD, in whom AU was found in 78,9%.
- 4 June 2026
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 31 (4) , 6424
Open AccessIncidence of chronic obstructive pulmonary disease in the newly diagnosed microalbuminuria population: retrospective analysis of the AURA registry database
Aim. To analyze the phenotypes of patients at highest risk for albuminuria (AU) in a population of patients without diabetes and to estimate its prevalence in the identified phenotypes. Material and methods. A total of 4580 patients over 40 years of age without type 1 or 2 diabetes, who had not previously been diagnosed with chronic kidney disease, were included in a real-world practice registry of AU detection in patients with previously undiagnosed CKD — AURA. The registry design did not include patient follow-up. AU was determined using sensitive micral-test strips, with an AU cutoff of 20 mg/L. Results. AU ≥20 mg/L was present in 64,9% of cases. According to univariate analysis, patients with AU compared with those without it were more likely to have the following risk factors: hypertension (79% vs 71,5%), male sex (44,2% vs 38,6%), smoking (31% vs 25,2%), metabolic syndrome (32% vs 23,4%), as well as diseases such as coronary artery disease (35,5% vs 29,7%), heart failure (41,5% vs 35%), atrial fibrillation (17,3% vs 12,5%), prediabetes (14,7% vs 8,9%), chronic obstructive pulmonary disease (COPD) (7,67% vs 3,76%), chronic cystitis (5,35% vs 3,49%). A multivariate model revealed that age (with each 1-year increase in age, the risk of AU increased by 2%, p-value Conclusion. A multivariate analysis of AURA registry data confirmed that AU is independently associated with conditions such as post-infarction cardiosclerosis, atrial fibrillation, prediabetes, metabolic syndrome, chronic cystitis, and COPD. Of particular interest is the study and follow-up of patients with COPD, in whom AU was found in 78,9%.
- Open Access
- 29 August 2024
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 29 (7) , 5926
Analysis of data from the Russian AURA registry (real-world data registry on AlbUminuRia detection rate among patients with previously undiAgnosed chronic kidney disease)
Aim. To present data from the AURA Registry (real-world data registry on AlbUminuRia detection rate among patients with previously undiAgnosed chronic kidney disease). It is important to perform population studies both to study the occurrence of markers (albuminuria (AU), decreased glomerular filtration rate (GFR)) and the prevalence of chronic kidney disease (CKD), which will provide information on the actual detection rate of CKD and the related markers in territories included in the registry of research centers.Material and methods. The article presents the first data from the AURA registry. Recruitment was carried out from March 6, 2023 to January 23, 2024. Thirty-four research centers in various federal districts of the Russian Federation and 104 doctors took part in the recruitment. We included 4580 subjects over the age of 40 years who had no previously established diagnosis of CKD and did not have type 1 or type 2 diabetes. During recruitment, the researchers were guided by the AURA study protocol (Version 1.7/12-26-2022).Results. AU more than 20 mg/g was detected in 64,9% of cases. At the same time, AU is more common at GFR values that may correspond to stage 3A of CKD. The rarer occurrence of AU in those examined with GFR >60 ml/min/1,73 m2 may be explained by less severe renal damage at this CKD stage. The incidence of AU was significantly higher in men, older people, smokers, people with metabolic syndrome, hypertension (HTN), prediabetes and overweight. The occurrence of AU also increased as HTN grade increased. AU detection rate was associated with hypertriglyceridemia, a high blood level of C-reactive protein, which is an integrative marker of inflammation that negatively affects cardiovascular risk.Conclusion. The presented first data from the AURA registry demonstrated the high AU prevalence in people over 40 years of age. A high incidence of AU was typical for patients with HTN, coronary artery disease, atrial fibrillation, heart failure, and prediabetes. An association has been demonstrated between the high incidence of AU and male sex, age, overweight, hyperuricemia, dyslipidemia, and a number of other cardiovascular risk factors.
- 29 August 2024
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 29 (7) , 5926
Open AccessAnalysis of data from the Russian AURA registry (real-world data registry on AlbUminuRia detection rate among patients with previously undiAgnosed chronic kidney disease)
Aim. To present data from the AURA Registry (real-world data registry on AlbUminuRia detection rate among patients with previously undiAgnosed chronic kidney disease). It is important to perform population studies both to study the occurrence of markers (albuminuria (AU), decreased glomerular filtration rate (GFR)) and the prevalence of chronic kidney disease (CKD), which will provide information on the actual detection rate of CKD and the related markers in territories included in the registry of research centers.Material and methods. The article presents the first data from the AURA registry. Recruitment was carried out from March 6, 2023 to January 23, 2024. Thirty-four research centers in various federal districts of the Russian Federation and 104 doctors took part in the recruitment. We included 4580 subjects over the age of 40 years who had no previously established diagnosis of CKD and did not have type 1 or type 2 diabetes. During recruitment, the researchers were guided by the AURA study protocol (Version 1.7/12-26-2022).Results. AU more than 20 mg/g was detected in 64,9% of cases. At the same time, AU is more common at GFR values that may correspond to stage 3A of CKD. The rarer occurrence of AU in those examined with GFR >60 ml/min/1,73 m2 may be explained by less severe renal damage at this CKD stage. The incidence of AU was significantly higher in men, older people, smokers, people with metabolic syndrome, hypertension (HTN), prediabetes and overweight. The occurrence of AU also increased as HTN grade increased. AU detection rate was associated with hypertriglyceridemia, a high blood level of C-reactive protein, which is an integrative marker of inflammation that negatively affects cardiovascular risk.Conclusion. The presented first data from the AURA registry demonstrated the high AU prevalence in people over 40 years of age. A high incidence of AU was typical for patients with HTN, coronary artery disease, atrial fibrillation, heart failure, and prediabetes. An association has been demonstrated between the high incidence of AU and male sex, age, overweight, hyperuricemia, dyslipidemia, and a number of other cardiovascular risk factors.
- 23 April 2024
- Published by Media Sphere Publishing Group in Medical Technologies. Assessment and Choice
- Vol. 46 (4)
COVID-19 and pneumonia — mortality and coding features (example of the Moscow region)
Objective. To analyze the peculiarities of COVID-19 and pneumonia group codes in medical death certificates considering demographic characteristics and place of death during the pandemic (2020—2022). Material and methods. We obtained data from the regional electronic database of the Main Directorate of the Civil Registry Office. Anonymized medical death certificate data on deceased persons aged ≥18 years were analyzed. Mortality rates for men and women aged ≥18 years from COVID-19 (U07.01-07.02) combined with pneumonia (codes J12-J18) were estimated. Results. Mortality from COVID-19 (codes U07.01-07.02) combined with pneumonia (codes J12-J18) comprised 9.4% of total number of dead in 2020, 21.4% in 2021 and 7.5% in 2022. Mortality rates were 165.1, 399.1 and 108.3 per 100.000, respectively. Mean age of deceased women was higher compared to deceased men. In 2020, mortality was higher among men. Deaths outside of hospital comprised 2.8% in 2020, 1.9% in 2021 and 2.8% in 2022. Codes U07.01 (COVID-19, virus identified) were used in 35.5% and 57.9% (p<0.0001) of cases in 2020 and 2022, respectively. Code U07.02 (COVID-19, virus not identified) was more common in cases of death outside of hospital. Viral pneumonia (J12) accounted for 70.5% in 2020, 76% in 2021 and 79.6% in 2022. Other cases were pneumonias with codes of unknown bacterial etiology (J18, J15.8-9, J16.8-9). In medical death certificates of patients who died outside of hospital, code J12 was indicated in 98.7% of cases (over 3 years). Only 0.03% of death certificates designated 2 pneumonia codes indicating the possibility of mixed etiology. Conclusion. Incidence of codes U07.01 and U07.02 has changed in 2020—2022. The overwhelming majority of death certificates indicate combinations of COVID-19 codes with virus-associated lung lesions. Analysis based on these certificates does not allow identifying the contribution of mixed infections.
- 23 April 2024
- Published by Media Sphere Publishing Group in Medical Technologies. Assessment and Choice
- Vol. 46 (4)
COVID-19 and pneumonia — mortality and coding features (example of the Moscow region)
Objective. To analyze the peculiarities of COVID-19 and pneumonia group codes in medical death certificates considering demographic characteristics and place of death during the pandemic (2020—2022). Material and methods. We obtained data from the regional electronic database of the Main Directorate of the Civil Registry Office. Anonymized medical death certificate data on deceased persons aged ≥18 years were analyzed. Mortality rates for men and women aged ≥18 years from COVID-19 (U07.01-07.02) combined with pneumonia (codes J12-J18) were estimated. Results. Mortality from COVID-19 (codes U07.01-07.02) combined with pneumonia (codes J12-J18) comprised 9.4% of total number of dead in 2020, 21.4% in 2021 and 7.5% in 2022. Mortality rates were 165.1, 399.1 and 108.3 per 100.000, respectively. Mean age of deceased women was higher compared to deceased men. In 2020, mortality was higher among men. Deaths outside of hospital comprised 2.8% in 2020, 1.9% in 2021 and 2.8% in 2022. Codes U07.01 (COVID-19, virus identified) were used in 35.5% and 57.9% (p<0.0001) of cases in 2020 and 2022, respectively. Code U07.02 (COVID-19, virus not identified) was more common in cases of death outside of hospital. Viral pneumonia (J12) accounted for 70.5% in 2020, 76% in 2021 and 79.6% in 2022. Other cases were pneumonias with codes of unknown bacterial etiology (J18, J15.8-9, J16.8-9). In medical death certificates of patients who died outside of hospital, code J12 was indicated in 98.7% of cases (over 3 years). Only 0.03% of death certificates designated 2 pneumonia codes indicating the possibility of mixed etiology. Conclusion. Incidence of codes U07.01 and U07.02 has changed in 2020—2022. The overwhelming majority of death certificates indicate combinations of COVID-19 codes with virus-associated lung lesions. Analysis based on these certificates does not allow identifying the contribution of mixed infections.
- Open Access
- 24 February 2024
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 29 (2) , 5806
Assessment of vascular age and cardiovascular risk factors among young women in the Moscow region
Aim. To assess vascular age (VA) and the main cardiovascular risk factors (chronological age, body mass index (BMI), carotid-femoral pulse wave velocity (PWV), blood pressure (BP)) in women in the Moscow region.Material and methods. We assessed BP levels, BMI, PWV, and also calculate vascular age for women participating in the forum. BMI was calculated using the Quetelet index as weight divided by height squared (BMI=kg/m2). BP levels were measured in a sitting position three times on both arms, with the highest result recorded. PWV and vascular age were calculated using AngioScan01. The association between anthropometric measures, vascular stiffness, and VA differences was examined using multivariate linear regression, adjusting for traditional cardiovascular risk factors. Intergroup (systolic blood pressure Results. The study involved 260 women. The mean age was 44,92±0,85 years (95% confidence interval (CI) 43,27-46,57), mean vascular age — 45,90±1,01 (95% CI 43,91-47,89), mean BMI — 23,383±0,66 kg/m2 (95% CI 22,046-24,720). Mean systolic BP was 127,63±1,89 mm Hg (95% CI 123,89-131,36), diastolic BP 80,031±0,93 (95% CI 78,20-81,86), mean PWV was 11,38±0,16 m/sec (95% CI 11,05-11,70). Analysis of the VA difference between women with BMI 2 (BMI1, n=93) and ≥25 kg/m2 (BMI2, n=67) revealed a significant difference in the calculated VA values (p=0,0002) between groups.Conclusion. Modern young women have high rates of vascular stiffness, which may determine the increase in morbidity and mortality rates in the working-age female population. The VA indicator predicts cardiovascular events and can be considered as an effective screening method for assessing cardiovascular risk, which is especially important for young patients.
- 24 February 2024
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 29 (2) , 5806
Open AccessAssessment of vascular age and cardiovascular risk factors among young women in the Moscow region
Aim. To assess vascular age (VA) and the main cardiovascular risk factors (chronological age, body mass index (BMI), carotid-femoral pulse wave velocity (PWV), blood pressure (BP)) in women in the Moscow region.Material and methods. We assessed BP levels, BMI, PWV, and also calculate vascular age for women participating in the forum. BMI was calculated using the Quetelet index as weight divided by height squared (BMI=kg/m2). BP levels were measured in a sitting position three times on both arms, with the highest result recorded. PWV and vascular age were calculated using AngioScan01. The association between anthropometric measures, vascular stiffness, and VA differences was examined using multivariate linear regression, adjusting for traditional cardiovascular risk factors. Intergroup (systolic blood pressure Results. The study involved 260 women. The mean age was 44,92±0,85 years (95% confidence interval (CI) 43,27-46,57), mean vascular age — 45,90±1,01 (95% CI 43,91-47,89), mean BMI — 23,383±0,66 kg/m2 (95% CI 22,046-24,720). Mean systolic BP was 127,63±1,89 mm Hg (95% CI 123,89-131,36), diastolic BP 80,031±0,93 (95% CI 78,20-81,86), mean PWV was 11,38±0,16 m/sec (95% CI 11,05-11,70). Analysis of the VA difference between women with BMI 2 (BMI1, n=93) and ≥25 kg/m2 (BMI2, n=67) revealed a significant difference in the calculated VA values (p=0,0002) between groups.Conclusion. Modern young women have high rates of vascular stiffness, which may determine the increase in morbidity and mortality rates in the working-age female population. The VA indicator predicts cardiovascular events and can be considered as an effective screening method for assessing cardiovascular risk, which is especially important for young patients.
- Open Access
- 14 December 2022
- Published by Intermedservice Ltd in Systemic Hypertension
- Vol. 19 (2) , 17-26
Results of a Russian multicenter open prospective study of the efficacy and safety of Telmista® and Telmista® H in patients with arterial hypertension 1 and 2 degrees
Relevance. The proportion of angiotensin receptor blockers has increased significantly among prescribed antihypertensive agents. To a large extent, this is facilitated by the emergence of new high-quality generic drugs available to the widest range of patients.Study objectives. Evaluation of effectiveness and safety of Telmista® (Telmisartan 40 mg, 80 mg, tablets, JSC Krka, d.d., Novo Mesto, Slovenia) and Telmista® H (hydrochlorothiazide + telmisartan 12.5 mg + 40 mg , 12.5 mg + 80 mg, 25 mg + 80 mg, tablets, JSC «Krka, dd, Novo Mesto», Slovenia) in patients with arterial hypertension of 1 and 2 degrees.Materials and methods. The study included 50 patients, 25 men and 25 women with arterial hypertension of 1–2 degrees. All patients underwent office blood pressure assessment, 24-hour blood pressure monitoring (ABPM), total cholesterol, HDL cholesterol, LDL cholesterol, TG, creatinine, glucose, insulin and glycated hemoglobin levels, HOMA index was calculated, urine microalbumin was determined, LV myocardial mass and LVMI were assessed according to ECHOCG at baseline and throughout the study. BP was re-measured after 4, 8, 12, 16, 20, 24 weeks of therapy, ABPM - after 16 weeks, the rest of the listed examinations - after 24 weeks.Results. During therapy with Telmista® and Telmista® H, 89% of patients with grade 1–2 AH achieved the target BP level, which was accompanied by an improvement in the metabolic profile, a decrease in LVMI and urinary microalbumin (in 50% of patients), alongside with an improvement in the quality of life after 24 weeks treatment. Thus, due to high antihypertensive and organoprotective efficacy, excellent tolerability and availability, Telmista® and Telmista® can be the drugs of choice in hypertensive patients, especially those with metabolic disorders, to maximize the reduction of cardiovascular risk in this category of patients.
- 14 December 2022
- Published by Intermedservice Ltd in Systemic Hypertension
- Vol. 19 (2) , 17-26
Open AccessResults of a Russian multicenter open prospective study of the efficacy and safety of Telmista® and Telmista® H in patients with arterial hypertension 1 and 2 degrees
Relevance. The proportion of angiotensin receptor blockers has increased significantly among prescribed antihypertensive agents. To a large extent, this is facilitated by the emergence of new high-quality generic drugs available to the widest range of patients.Study objectives. Evaluation of effectiveness and safety of Telmista® (Telmisartan 40 mg, 80 mg, tablets, JSC Krka, d.d., Novo Mesto, Slovenia) and Telmista® H (hydrochlorothiazide + telmisartan 12.5 mg + 40 mg , 12.5 mg + 80 mg, 25 mg + 80 mg, tablets, JSC «Krka, dd, Novo Mesto», Slovenia) in patients with arterial hypertension of 1 and 2 degrees.Materials and methods. The study included 50 patients, 25 men and 25 women with arterial hypertension of 1–2 degrees. All patients underwent office blood pressure assessment, 24-hour blood pressure monitoring (ABPM), total cholesterol, HDL cholesterol, LDL cholesterol, TG, creatinine, glucose, insulin and glycated hemoglobin levels, HOMA index was calculated, urine microalbumin was determined, LV myocardial mass and LVMI were assessed according to ECHOCG at baseline and throughout the study. BP was re-measured after 4, 8, 12, 16, 20, 24 weeks of therapy, ABPM - after 16 weeks, the rest of the listed examinations - after 24 weeks.Results. During therapy with Telmista® and Telmista® H, 89% of patients with grade 1–2 AH achieved the target BP level, which was accompanied by an improvement in the metabolic profile, a decrease in LVMI and urinary microalbumin (in 50% of patients), alongside with an improvement in the quality of life after 24 weeks treatment. Thus, due to high antihypertensive and organoprotective efficacy, excellent tolerability and availability, Telmista® and Telmista® can be the drugs of choice in hypertensive patients, especially those with metabolic disorders, to maximize the reduction of cardiovascular risk in this category of patients.
- 1 January 2020
- Published by Dynasty Publishing House in Infekcionnye bolezni
- Vol. 18 (3)
Treatment of acute respiratory viral infections: results of a multicenter, double-blind, placebo-controlled, randomized clinical trial
This multicenter, double-blind, placebo-controlled clinical trial was conducted to obtain additional data on the efficacy and safety of Anaferon for the treatment of acute respiratory viral infections (ARVI) during seasonal increase in their incidence (RCT of the Ministry of Health of Russia No 356 dated 24.07.2018; ClinicalTrials.gov Identifier: NCT03707912). Patients and methods. Between October 2018 and March 2019, a total of 204 patients aged 18 to 70 years with ARVI symptoms were included in this study within the first 24 hours of symptom onset. Patients were randomized into 2 groups: 104 individuals received oral Anaferon (should be kept in the mouth until completely dissolved and without food) according to the following scheme: 1 tablet every 30 minutes during the first 2 hours; then 3 more doses at regular intervals during the first day; then 1 tablet 3 times a day on days 2–5; 100 individuals received placebo according to the same scheme. The primary endpoint was time to resolution of symptoms of clinically diagnosed and/or PCR (polymerase chain reaction) – confirmed ARVI. Addithional endpoints included: time to resolution of symptoms of ARVI confirmed by PCR; proportion of patients with resolution of symptoms of clinically diagnosed and/or PCR-confirmed ARVI and separately PCR-confirmed ARVI; severity of clinically diagnosed and/or PCR-confirmed ARVI (assessed by ‘area under the curve’ for the total severity index); the number of antipyretic doses taken according to indications on days 1–3 of treatment (checked in the patient's diary); proportion of patients who required antibiotic treatment on days 4–7 of follow-up. To assess safety, we analyzed the incidence and type of adverse events (AEs), their severity, association with drug use, and treatment outcome. The following statistical methods were used: Fisher's exact test, Cochran–Mantel–Haenszel test, Wilcoxon test, and repeated measures ANOVA, PROC MIXED. Results. A total of 203 patients were included in the intention-to-treat (ITT) and per protocol (РР) analysis: 103 [95] individuals in the Anaferon arm and 100 [93] individuals in the Placebo arm. Patients receiving Anaferon had significantly shorter time to resolution of all ARVI symptoms than patients receiving placebo: 4.1 ± 1.6 days vs 4.5 ± 1.5 days (p = 0.032). The disease was on average 1 day shorter in patients from the experimental group compared to controls: 3.6 ± 1.5 days vs 4.6 ± 1.5 days (p = 0.007). The proportion of patients who had resolution of symptoms of clinically diagnosed and/or PCR-confirmed ARVI was significantly higher in the Anaferon arm compared to Placebo arm (p = 0.0012). Among patients with PCR-verified ARVI, treatment with Anaferon resulted in twice as frequent recovery as in the control group on day 4 (53.7% vs 26.3%) and day 7 (70.7% vs 36.8%). In the Anaferon arm, we observed shorter disease duration and higher proportion of patients recovered compared to the Placebo arm; however, patients in both groups had a similar need for antipyretic drugs on days 1–3 of treatment, as well as for antibiotic therapy. The incidence of AEs in the Anaferon and Placebo groups did not vary significantly. No AEs with a reliable association with Anaferon were registered. Conclusion. Our findings suggest high efficacy and safety of Anaferon in patients with ARVI. The best results were obtained in patients with PCR-verified diagnosis, which can be attributed to the involvement of the interferon system in the action of the drug. The results of this RCT confirm the data obtained in previous studies and long-term clinical experience of using Anaferon. Key words: acute respiratory viral infections, ARVI, treatment, effective therapy, placebo-controlled study, Anaferon, randomized clinical trial, comprehensive therapy, efficacy, safety
- 1 January 2020
- Published by Dynasty Publishing House in Infekcionnye bolezni
- Vol. 18 (3)
Treatment of acute respiratory viral infections: results of a multicenter, double-blind, placebo-controlled, randomized clinical trial
This multicenter, double-blind, placebo-controlled clinical trial was conducted to obtain additional data on the efficacy and safety of Anaferon for the treatment of acute respiratory viral infections (ARVI) during seasonal increase in their incidence (RCT of the Ministry of Health of Russia No 356 dated 24.07.2018; ClinicalTrials.gov Identifier: NCT03707912). Patients and methods. Between October 2018 and March 2019, a total of 204 patients aged 18 to 70 years with ARVI symptoms were included in this study within the first 24 hours of symptom onset. Patients were randomized into 2 groups: 104 individuals received oral Anaferon (should be kept in the mouth until completely dissolved and without food) according to the following scheme: 1 tablet every 30 minutes during the first 2 hours; then 3 more doses at regular intervals during the first day; then 1 tablet 3 times a day on days 2–5; 100 individuals received placebo according to the same scheme. The primary endpoint was time to resolution of symptoms of clinically diagnosed and/or PCR (polymerase chain reaction) – confirmed ARVI. Addithional endpoints included: time to resolution of symptoms of ARVI confirmed by PCR; proportion of patients with resolution of symptoms of clinically diagnosed and/or PCR-confirmed ARVI and separately PCR-confirmed ARVI; severity of clinically diagnosed and/or PCR-confirmed ARVI (assessed by ‘area under the curve’ for the total severity index); the number of antipyretic doses taken according to indications on days 1–3 of treatment (checked in the patient's diary); proportion of patients who required antibiotic treatment on days 4–7 of follow-up. To assess safety, we analyzed the incidence and type of adverse events (AEs), their severity, association with drug use, and treatment outcome. The following statistical methods were used: Fisher's exact test, Cochran–Mantel–Haenszel test, Wilcoxon test, and repeated measures ANOVA, PROC MIXED. Results. A total of 203 patients were included in the intention-to-treat (ITT) and per protocol (РР) analysis: 103 [95] individuals in the Anaferon arm and 100 [93] individuals in the Placebo arm. Patients receiving Anaferon had significantly shorter time to resolution of all ARVI symptoms than patients receiving placebo: 4.1 ± 1.6 days vs 4.5 ± 1.5 days (p = 0.032). The disease was on average 1 day shorter in patients from the experimental group compared to controls: 3.6 ± 1.5 days vs 4.6 ± 1.5 days (p = 0.007). The proportion of patients who had resolution of symptoms of clinically diagnosed and/or PCR-confirmed ARVI was significantly higher in the Anaferon arm compared to Placebo arm (p = 0.0012). Among patients with PCR-verified ARVI, treatment with Anaferon resulted in twice as frequent recovery as in the control group on day 4 (53.7% vs 26.3%) and day 7 (70.7% vs 36.8%). In the Anaferon arm, we observed shorter disease duration and higher proportion of patients recovered compared to the Placebo arm; however, patients in both groups had a similar need for antipyretic drugs on days 1–3 of treatment, as well as for antibiotic therapy. The incidence of AEs in the Anaferon and Placebo groups did not vary significantly. No AEs with a reliable association with Anaferon were registered. Conclusion. Our findings suggest high efficacy and safety of Anaferon in patients with ARVI. The best results were obtained in patients with PCR-verified diagnosis, which can be attributed to the involvement of the interferon system in the action of the drug. The results of this RCT confirm the data obtained in previous studies and long-term clinical experience of using Anaferon. Key words: acute respiratory viral infections, ARVI, treatment, effective therapy, placebo-controlled study, Anaferon, randomized clinical trial, comprehensive therapy, efficacy, safety